Viridian Therapeutics, Inc.\DE (VRDN) Assets Average (2014 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Assets Average of $844.2 million for Q1 2026, up 20.31% year-over-year from $701.7 million in Q1 2025, and up 14.35% quarter-over-quarter from $738.3 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Assets Average (2014 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Assets Average history runs 13 years deep, the most recent figure standing at $844.2 million for Q1 2026.
- In Q1 2026, Assets Average rose 20.31% year-over-year to $844.2 million; the TTM figure through Mar 2026 stood at $844.2 million (up 20.31% YoY), while the FY2025 annual figure was $820.9 million, up 33.18% from the prior year.
- Assets Average for Q1 2026 stood at $844.2 million, up from $738.3 million in the prior quarter.
- The five-year high for Assets Average was $844.2 million in Q1 2026, with the low at $176.5 million in Q2 2022.
- The 5-year median for Assets Average is $560.4 million (2024), against an average of $513.7 million.
- The sharpest annual moves came in 2023 and 2025: Assets Average jumped 112.4% in 2023, then slipped 14.59% in 2025.
- Viridian Therapeutics, Inc.\DE's Assets Average stood at $437.8 million in 2022, then decreased by 6.45% to $409.6 million in 2023, then jumped by 84.86% to $757.2 million in 2024, then decreased by 2.49% to $738.3 million in 2025, then increased by 14.35% to $844.2 million in 2026.
- Business Quant data shows VRDN's Assets Average at $844.2 million in Q1 2026, $738.3 million in Q4 2025, and $579.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 943.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 943.13 Mn |
| Mar 31, 2026 | 844.22 Mn |
| Dec 31, 2025 | 738.28 Mn |
| Sep 30, 2025 | 579.73 Mn |
| Jun 30, 2025 | 621.65 Mn |
| Mar 31, 2025 | 701.69 Mn |
| Dec 31, 2024 | 757.15 Mn |
| Sep 30, 2024 | 678.78 Mn |
| Jun 30, 2024 | 608.02 Mn |
| Mar 31, 2024 | 560.40 Mn |
| Dec 31, 2023 | 409.59 Mn |
| Sep 30, 2023 | 340.11 Mn |
| Jun 30, 2023 | 369.05 Mn |
| Mar 31, 2023 | 410.87 Mn |
| Dec 31, 2022 | 437.84 Mn |
| Sep 30, 2022 | 305.20 Mn |
| Jun 30, 2022 | 176.49 Mn |
| Mar 31, 2022 | 193.44 Mn |
| Dec 31, 2021 | 212.46 Mn |
| Sep 30, 2021 | 169.70 Mn |